Independence from Cancer on July 4thPosted: July 3, 2017 Filed under: Uncategorized Comments Off on Independence from Cancer on July 4th
This Fourth of July holiday, we’re not only celebrating the red, white and blue that honors the independence and freedom of our country, but also freedom from cancer and the cancer “blues.” Feeling this sense of freedom may mean that you’re cancer-free or that you’re unwilling to let a cancer diagnosis define you.
To be cancer-free means that tests show no evidence of any cancer remaining in the body, a term coined “complete remission.” In some cases, it is possible to complete treatment but still have some evidence of the cancer. This is called “partial remission.”
At Weill Cornell Medicine and NewYork-Presbyterian Hospital, many of our patients and their families experience a wide range of emotions during and after cancer treatment. Often, freedom from cancer is both something to celebrate and something that comes with an air of caution. That’s because the joy of being cancer-free may be accompanied by fear that the cancer may return.
Fighting cancer is a tremendously emotional experience, so take comfort in the fact that you’re not alone. For patients dealing with any cancer diagnosis, Weill Cornell Medicine and NewYork-Presbyterian offer a patient support group on the first and third Thursday of every month from 12-1p.m. For more information about this safe and supportive place for those dealing with any cancer diagnosis, please contact Susan Marchal at (212) 746–9039.
Have a wonderful holiday!
This article originally appeared on “What’s New In GU?,” a blog from the NewYork-Presbyterian/Weill Cornell Genitourinary (GU) Oncology Program.
Newly-Opened Clinical Trial for People with Acute Myeloid LeukemiaPosted: May 28, 2017 Filed under: Uncategorized Comments Off on Newly-Opened Clinical Trial for People with Acute Myeloid Leukemia
Dr. Gail J. Roboz is the principal investigator for a new immunotherapy clinical trial at Weill Cornell Medicine and NewYork-Presbyterian for people with acute myeloid leukemia (AML). The clinical trial is evaluating engineered CAR-T cells, UCART123, that have been specially engineered in the laboratory to be able to target a molecule on the surface of leukemia cells called CD123. It is hoped that the T cells will be able to destroy the CD123 positive leukemia cells and lead to remission in selected patients with AML.
Contact us or click here to learn more: http://bit.ly/2rpQso8
Dr. Gail Roboz to Lead Clinical Trial in AML for Novel Immunotherapy, UCART123Posted: February 27, 2017 Filed under: Uncategorized Comments Off on Dr. Gail Roboz to Lead Clinical Trial in AML for Novel Immunotherapy, UCART123
In the summer of 2015, Weill Cornell Medical College and Cellectis, a French pharmaceutical company, announced a translational research collaboration for a new allogeneic chimeric antigen receptor T cell therapy called UCART123. This “off-the-shelf” product is a directed immunotherapy for patients with acute myeloid leukemia (AML), an aggressive blood cancer. T cells are harvested from healthy donors and engineered to target the CD123 antigen, which is found on AML blast and stem cells, as well as tumor cells in another aggressive malignancy, blastic plasmacytoid dendritic cell neoplasm (BPDCN).
The clinical trial of UCART123 in AML is being led by principal investigator Dr. Gail J. Roboz, Professor of Medicine and Director of the Leukemia Program at Weill Cornell Medicine and NewYork-Presbyterian. Translational scientific studies for the trial are being conducted in the laboratory of Dr. Monica Guzman, Associate Professor of Pharmacology in Medicine, also at Weill Cornell. Clinical research on UCART123 in BPDCN will be led by Dr. Naveen Pemmaraju and Dr. Hagop Kantarjian at the MD Anderson Cancer Center in Houston, Texas.
Stay tuned for more updates regarding the new phase 1 clinical trial for UCART123 to be initiated here at the Leukemia Program in the coming months.
New Classifications for Myelodysplastic Syndromes (MDS)Posted: January 17, 2017 Filed under: CRUSH!!MDS, Uncategorized | Tags: cancer, hematology, Leukemia, MDS, Myelodysplastic Syndrome, Oncology, Research, Weill Cornell Medical College Comments Off on New Classifications for Myelodysplastic Syndromes (MDS)
Dr. Ellen Ritchie recently participated in an OncLive discussion on the latest modifications to the World Health Organization (WHO) classification of Myelodysplastic Syndromes (MDS). WHO classification is the standard diagnostic system utilized by medical institutions worldwide, including here at Weill Cornell Medicine. Recent advances in our understanding of the biological course of MDS have warranted revision to its WHO classification, which was last updated in 2008. In particular, mutational and cytogenetic analyses have to led to refinement of diagnostic terms for MDS. These modifications include a distinction between single versus multilineage dysplasia and elimination of the term “cytopenia.”
The OncLive discussion centered on implications of the new classification on the prognosis and treatment of MDS. While the WHO classification is just one of many factors to consider when evaluating the prognosis of the disorder, the panelists agree that the new modifications will make it easier to determine an appropriate course of treatment for their patients. To learn more, click here or watch the video below.
Weill Cornell Leukemia Program Abstracts @ ASH 2016Posted: December 5, 2016 Filed under: Leukemia News, Uncategorized | Tags: acute lymphocytic leukemia, Acute Myeloid Leukemia, ALL, AML, Blood Disorders, bone marrow, cancer, cancer treatment, chemotherapy, CML, hematology, Leukemia, Leukemia News, MDS, Oncology, Research Comments Off on Weill Cornell Leukemia Program Abstracts @ ASH 2016
December is an exciting month here at the Leukemia Program, as each year, our doctors and researchers are invited to attend and present their work at the annual meeting of the American Society of Hematology (ASH). This important meeting provides the opportunity to network with thousands of hematology specialists from all over the world.
This year, the 58th ASH Annual Meeting & Exposition is being held December 3-6 in San Diego, California. We are very proud to play an integral role in research that is changing the way leukemia is diagnosed, tracked and treated. The below abstracts are being presented in oral or poster sessions by the Leukemia Program’s physicians, researchers, and collaborators.
#98. Results of a Clinical Study of Pevonedistat (Pev), a First-in-Class NEDD8-Activating Enzyme (NAE) Inhibitor, Combined with Azacitidine (Aza) in Older Patients (Pts) with Acute Myeloid Leukemia
#226. A Randomized Phase II Study of Low-Dose Decitabine Versus Azacitidine in Patients with Low- or Intermediate-1-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
#433. Cooperative Epigenetic Remodeling By TET2 Loss and NRAS Mutation Drives Myeloid Transformation and MEK Inhibitor Sensitivity
#438. BCL6 Is Critical to Overcome Oncogene-Induced Senescence in RAS-Mediated B Cell Transformation
#582. Acute Myeloid Leukemia Cells Resist Chemotherapy through a Reversible Senescence-like State Maintaining Repopulation Potential
#599. Changes of the Mutational Landscape in Relapsed Acute Myeloid Leukemia
#765. Allogeneic Tcrα/β Deficient CAR T-Cells Targeting CD123 Prolong Overall Survival of AML Patient-Derived Xenografts
#902. Analysis of Efficacy By Age for Patients Aged 60–75 with Untreated Secondary Acute Myeloid Leukemia (AML) Treated with CPX-351 Liposome Injection Versus Conventional Cytarabine and Daunorubicin in a Phase III Trial Clinically Relevant Abstract
#903. Durable Overall Survival Benefit in Patients ≥ 60 Years with Relapsed or Refractory AML Treated with Vosaroxin/Cytarabine Vs Placebo/Cytarabine: Updated Results from the Valor Trial
#904. Long Term Survival and Clinical Complete Responses of Various Prognostic Subgroups in 103 Relapsed/Refractory Acute Myeloid Leukemia (r/r AML) Patients Treated with Guadecitabine (SGI-110) in Phase 2 Studies
#906. Survival Following Allogeneic Hematopoietic Cell Transplantation in Older High-Risk Acute Myeloid Leukemia Patients Initially Treated with CPX-351 Liposome Injection Versus Standard Cytarabine and Daunorubicin: Subgroup Analysis of a Large Phase III Trial
#1048. Cooperative Gene Repression By DNA Methylation and LSD1-Mediated Enhancer Inactivation in Acute Myeloid Leukemia
#1063. The Use of Hypomethylating Agents (HMAs) in Patients with Relapsed and Refractory Acute Myeloid Leukemia (RR-AML): Clinical Outcomes and Their Predictors in a Large International Patient Cohort
#1069. Final Results of the Chrysalis Trial: A First-in-Human Phase 1/2 Dose-Escalation, Dose-Expansion Study of Gilteritinib (ASP2215) in Patients with Relapsed/Refractory Acute Myeloid Leukemia
#1070. Determination of IDH1 Mutational Burden and Clearance Via Next-Generation Sequencing in Patients with IDH1 Mutation-Positive Hematologic Malignancies Receiving AG-120, a First-in-Class Inhibitor of Mutant IDH1
#1077. CD97 Is a Critical Regulator of Acute Myeloid Leukemia Stem Cell Function
#1553. PI3 Kinase p110 Delta Is Required for Leukemic Cell Survival and Self-Renewal in t(8;21) Acute Myeloid Leukemia
#1680. Genetic Determinants of Response to Guadecitabine (SGI-110) in AML
#1693. Selection and Characterization of Antibody Clones Are Critical for Accurate Flow Cytometry-Based Monitoring of CD123 in Acute Myeloid Leukemia
#2011. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia
#2816. Thioguanine Combined with Decitabine Can Overcome Resistance to Hypomethylating Agents: Final Results of a Phase I Trial of a Pharmacodynamically-Conceived Thioguanine/Decitabine Combination in Patients with Advanced Myeloid Malignancies
#2888. Minimal Residual Disease Assessment of Common and Rare NPM1 Mutations Using a Single Massively Multiplex Digital PCR Assay
#3548. Current Diagnosis Patterns for Acute Myeloid Leukemia (AML) in Clinical Practice Compared with World Health Organization (WHO) 2008 Recommendations: Outcomes from the CONNECT® Myelodysplastic Syndromes (MDS) and AML Disease Registry
#4039. Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
#279. The Pro-Tumorigenic Vascular Niche Sustains the T-Cell Acute Lymphoblastic Leukemia Phenotype and Fosters Resistance to Therapy
#907. Oncogenic Feedback Activation Between BCL6 and MLL Promotes Malignant Transformation in MLL-Rearranged Acute Lymphoblastic Leukemia
#1629. A Pediatric-Inspired Regimen Containing Multiple Doses of Intravenous Pegylated Asparaginase Appears Safe and Effective in Newly Diagnosed Adult Patients with Ph-Negative Acute Lymphoblastic Leukemia in Adults up to Age 60: Results of a Multi-Center Phase II Clinical Trial
#4088. CD25 Enables Oncogenic BCR Signaling and Represents a Therapeutic Target in Refractory B Cell Malignancies
#3090. ENESTgoal Treatment-Free Remission Study: Updated Preliminary Results and Digital Polymerase Chain Reaction Analysis in Patients with Chronic Myeloid Leukemia in Chronic Phase Who Switched from Imatinib to Nilotinib
#479. Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia
#4271. Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial
#112. Frequency and Prognostic Significance of Cytogenetic Abnormalities in 1269 Patients with Therapy-Related Myelodysplastic Syndrome – a Study of the International Working Group (IWG-PM) for Myelodysplastic Syndromes
#297. Is Serial Monitoring of Myeloid Mutations Clinically Relevant in Myelodysplastic Syndromes (MDS): A Report on Behalf of the MDS Clinical Research Consortium (CRC)
#343. Enasidenib (AG-221), a Potent Oral Inhibitor of Mutant Isocitrate Dehydrogenase 2 (IDH2) Enzyme, Induces Hematologic Responses in Patients with Myelodysplastic Syndromes
#964. Runx1 Deficiency and MDS-Associated U2af1 Mutation Cooperate for Leukemia Development in a New Mouse Model
#2011. Comprehensive Analysis of Safety: Rigosertib in 557 Patients with Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)
#4321. Ring Sideroblasts and SF3B1 Mutations in Myelodysplastic Syndromes (MDS): Are They Two Faces of the Same Coin? a Study on Behalf of the MDS Clinical Research Consortium (MDS CRC)
#4322. Optimal Treatment Order of Lenalidomide and Hypomethylating Agents for Lower-Risk Myelodysplastic Syndromes: A Report on Behalf of the MDS Clinical Research Consortium
#4332. Importance of Complete Remission on Predicting Overall Survival in Patients with Lower-Risk Myelodysplastic Syndromes